acute myocardial infarction

stent-liberador-de-zotarolimus

RESOLUTE Global: 5 Years of Zotarolimus DES Stenting

This study assessed the cumulative incidence of cardiovascular evens after zotarolimus eluting stent implantation. &nbsp; Individual studies often lack enough statistical power to show differences in low frequency adverse events. The Resolute zotarolimus eluting stent was evaluated across 10 prospective clinical trials designed with identical adverse events definitions. &nbsp; The Global Resolute clinical trial program<a href="https://solaci.org/en/2017/03/10/resolute-global-5-years-of-zotarolimus-des-stenting/" title="Read more" >...</a>

See the Presentations of the 2016 Chile Sessions

We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below &nbsp; Lluberas, Ricardo. &#8220;Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin<a href="https://solaci.org/en/2017/01/07/see-the-presentations-of-the-2016-chile-sessions/" title="Read more" >...</a>

Momento de la estrategia invasiva luego de un infarto sin supradesnivel del ST

Post NSTEMI Invasive Strategy Timing

The aim of this meta-analysis, which included all randomized studies carried out to date, was to compare an early invasive strategy vs. a delayed invasive strategy in patients undergoing non ST elevation myocardial infarction (NSTEMI). &nbsp; Even though there is no doubt invasive strategies reduce events rate such as death and re-infarction in NSTEMI patients,<a href="https://solaci.org/en/2016/12/19/post-nstemi-invasive-strategy-timing/" title="Read more" >...</a>

ticagrelor vs prasugel

Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

No randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out in the last 7&nbsp;years since these newer P2Y12 inhibitors first showed a higher efficacy relative to clopidogrel. &nbsp; This study was designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with acute myocardial infarction<a href="https://solaci.org/en/2016/12/07/ticagrelor-vs-prasugel-similar-safety-and-efficacy-in-primary-angioplasty/" title="Read more" >...</a>

recanalizacion de cto en vaso no responsable

Rechanneling a CTO in a Non-Infarct-Related Artery After Primary PCI: Yes or No?

Between 10% and 15% of patients admitted with ST-segment elevation myocardial infarction present concurrent coronary chronic total occlusion (CTO) in a non-infarct-related artery, which is associated with increased morbidity and mortality. &nbsp; The EXPLORE (Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) trial evaluated whether patients admitted<a href="https://solaci.org/en/2016/10/12/rechanneling-a-cto-in-a-non-infarct-related-artery-after-primary-pci-yes-or-no/" title="Read more" >...</a>

angioplastia primaria estrategia farmacoinvasiva

Are Pharmacoinvasive Strategy and Primary PCI Comparable?

The Strategic Reperfusion Early After Myocardial Infarction trial and the French Registry of Acute Myocardial Infarction 2015 suggest that pharmacoinvasive strategy compares favorably with primary percutaneous coronary intervention (PCI). &nbsp; This study compared the impact of pharmacoinvasive strategy with the impact of primary angioplasty in real-world patients admitted with acute coronary syndrome with ST-segment elevation. &nbsp; The<a href="https://solaci.org/en/2016/09/26/are-pharmacoinvasive-strategy-and-primary-pci-comparable/" title="Read more" >...</a>

reserva fraccional de flujo sindrome coronario agudo

Deferring Lesions by FFR in ACS: Yes or No?

Deferring treatment through angioplasty in non-ischemic lesions by fractional flow reserve (FFR) is associated with excellent long-term prognosis in patients with chronic ischemic heart disease. &nbsp; FFR is beginning to be used for clinical decision-making in patients with acute coronary syndromes, and its long-term effect on stable chronic patients has not been established. &nbsp; This<a href="https://solaci.org/en/2016/09/21/deferring-lesions-by-ffr-in-acs-yes-or-no/" title="Read more" >...</a>

Prasugrel vs. Ticagrelor in Primary Angioplasty

The choice of prasugrel or ticagrelor for patients with acute myocardial infarction undergoing primary angioplasty makes no difference, at least in the short term. &nbsp; This study was terminated prematurely and thus lost statistical power, which means that any interpretation of the lack of difference between the two antiplatelet drugs must take into account such<a href="https://solaci.org/en/2016/09/07/prasugrel-vs-ticagrelor-in-primary-angioplasty/" title="Read more" >...</a>

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful coronary angioplasty in patients with stable chronic angina WITHOUT prior history of acute myocardial infarction or heart failure. &nbsp; The benefit of beta-blockers in patients with acute myocardial infarction or systolic heart failure is well documented. However, their<a href="https://solaci.org/en/2016/08/23/beta-blockers-for-revascularized-patients-to-prescribe-or-not/" title="Read more" >...</a>

cangrelor vs. clopidogrel infartos peri-procedimiento

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that have not previously received any other P2Y12 inhibitor. &nbsp; The CHAMPION PHOENIX trial randomized a total of 11,145 patients to cangrelor vs. clopidogrel. &nbsp; The study sought to explore the effect of cangrelor on peri-procedural acute myocardial infarction<a href="https://solaci.org/en/2016/08/22/peri-procedural-mi-reduction-cangrelor-or-clopidogrel/" title="Read more" >...</a>

Top